Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
Seven scientists at the Department of Energy’s Oak Ridge National Laboratory have been named Battelle Distinguished Inventors, in recognition of their obtaining 14 or more patents during their careers at the lab.
Laboratory Director Thomas Zacharia presented five Director’s Awards during Saturday night's annual Awards Night event hosted by UT-Battelle, which manages ORNL for the Department of Energy.
Marc-Antoni Racing has licensed a collection of patented energy storage technologies developed at ORNL. The technologies focus on components that enable fast-charging, energy-dense batteries for electric and hybrid vehicles and grid storage.
Two decades in the making, a new flagship facility for nuclear physics opened on May 2, and scientists from the Department of Energy’s Oak Ridge National Laboratory have a hand in 10 of its first 34 experiments.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
ORNL and The University of Toledo have entered into a memorandum of understanding for collaborative research.
A modern, healthy transportation system is vital to the nation’s economic security and the American standard of living. The U.S. Department of Energy’s Oak Ridge National Laboratory (ORNL) is engaged in a broad portfolio of scientific research for improved mobility
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.